Abstract
Purpose
Patients with estrogen receptor positive (ER+) breast cancer are often non-adherent to endocrine therapies, despite clear survival benefits. We utilized a nationally representative cancer cohort to examine the role of specific mental illnesses on endocrine therapy adherence.
Methods
Using the SEER-Medicare database, we included 21,894 women aged 68+ at their first surgically treated stage I-IV ER+ breast cancer during 2007–2013. All had continuous fee-for-service Medicare Parts A and B for 36+ months before, 18+ months after diagnosis, and continuous Part D for 4+ months before, 18+ after diagnosis. Mental illness was defined as occurring in the 36 months prior to cancer onset. We analyzed endocrine therapy adherence, initiation, and discontinuation using longitudinal linear and Cox regression models.
Results
Unipolar depression (11.0%), anxiety (9.5%), non-schizophrenia psychosis (4.6%), and dementias (4.6%) were the most prevalent diagnoses. Endocrine therapies were initiated by 80.0% of women. Among those with at least one year of use, 28.0% were non-adherent (< 0.80 adherence, mean = 0.84) and 25.7% discontinued. Patients with dementia or bipolar depression/psychotic/schizophrenia disorders had lower adjusted initiation probabilities by year one of follow-up, versus those without these diagnoses [0.74 95% CI (0.73–0.74) and 0.73 (0.72–0.73), respectively, reference 0.76 (0.76–0.77)]. Patients with substance use or anxiety disorders less frequently continued endocrine therapy for at least one year, after adjustment, [0.85 95% CI (0.85–0.86) and 0.88 (0.87–0.88), respectively, reference 0.90 (0.89–0.90)]. Patients with substance use disorders had 2.3% lower adherence rates (p < 0.001).
Conclusions
Nearly one-quarter of female Medicare beneficiaries have diagnosed mental illness preceding invasive breast cancer. Those with certain mental illnesses have modestly reduced rates of initiation, adherence, and discontinuation and this may help define patients at higher risk of treatment abandonment. Overall, endocrine therapy adherence remains suboptimal, unnecessarily worsening recurrence and mortality risk.
Similar content being viewed by others
Data availability
The SEER-Medicare data supporting the findings of this study are available from the National Cancer Institute but restrictions apply to the availability for these data, which were under license for the study, and are not available without approval. Data are available from the authors upon reasonable request and with permission of the National Cancer Institute.
References
Davies C et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816
Partridge AH et al (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21(4):602–606
Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120–4128
Doggrell SA et al (2011) Adherence to oral endocrine treatments in women with breast cancer: can it be improved? Breast Cancer Res Treat 129(2):299–308
Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537
Hadji P et al (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73(2):156–166
Land SR et al. (2016) Symptoms and QOL as predictors of chemoprevention adherence in NRG oncology/NSABP trial P-1. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv365
Mausbach BT et al (2015) Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 152(2):239–246
Iglay K et al (2017) Diagnosis and treatment delays among elderly breast cancer patients with pre-existing mental illness. Breast Cancer Res Treat 166(1):267–275
Iglay K et al (2017) Impact of preexisting mental illness on all-cause and breast cancer-specific mortality in elderly patients with breast cancer. J Clin Oncol 35(36):4012–4018
Howlader N at al (2017) SEER cancer statistics review, 1975–2014. National Cancer Institute, Rockville
NIH. SEER-medicare: SEER program and data. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/aboutdata/program.html
NIH. SEER-medicare: medicare claims files. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/medicare/claims.html#part_d
NIH. Breast Schema for 1988 + based on AJCC 6th edition. NIH Surveillance, Epidemiology, and End Results Program 2018. https://seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/breast.html
NIH. NCI Comorbidity Index Overview. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html
American Psychiatric Association (1994) Diagnostic and statistical manual, 6th edn. American Psychiatric Association, Washington DC
Tajeu GS et al (2016) Trends in antihypertensive medication discontinuation and low adherence among medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 68(3):565–575
Burstein HJ et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269
Hess LM et al (2006) Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 40(7–8):1280–1288
Chang A et al (2015) A SAS macro to calculate the PDC adjustment of inpatient stays. SAS Global Forum Proceedings 2015. Paper 3560
NIH. SEER-medicare: calculation of comorbidity weights. NIH Healthcare Delivery Research Program 2018. https://healthcaredelivery.cancer.gov/seermedicare/considerations/calculation.html
Akaike H (1981) Likelihood of a model and information criteria. J Econometr 16:3
Zhang X et al (2007) A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model (vol 88, pg 95, 2007). Computer Methods and Programs in Biomedicine 88(3):313–314
Pan W (2001) Akaike’s information criterion in generalized estimating equations. Biometrics 57(1):120–125
Insel KC et al (2006) The negative association of independent personality and medication adherence. J Aging Health 18(3):407–418
Arlt S et al (2008) Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging 25(12):1033–1047
Reus VI (2015) In: Kasper D (ed) Mental disorders, in Harrison’s principles of internal medicine, 19e. McGraw-Hill Education: New York
Lingam R, Scott J (2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand 105(3):164–172
De Hert M et al (2011) Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 10(2):138–151
Cruz ES et al (2014) Medical rehabilitation—substance abuse, in current diagnosis and treatment: physical medicine and rehabilitation. McGraw-Hill, New York
Leonard S et al (2001) Smoking and mental illness. Pharmacol Biochem Behav 70(4):561–570
Reus VI (2017) In: Jameson JL et al (eds) Psychiatric disorders, in Harrison’s principles of internal medicine, 20e. McGraw-Hill Education: New York
Marion D (2017) Psychological factors affecting other medical conditions: clinical features, assessment, and diagnosis, in uptodate. Waltham
Hudani ZK, Rojas-Fernandez CH (2016) A scoping review on medication adherence in older patients with cognitive impairment or dementia. Res Soc Adm Pharm 12(6):815–829
Rizzuto D et al (2017) Personality and survival in older age: the role of lifestyle behaviors and health status. Am J Geriatr Psychiatry 25(12):1363–1372
American College of Obstetricians and Gynecologists (2015) Committee Opinion No. 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol 125(6):1529-1537
Chapter 2: culture counts: the influence of culture and society on mental health. US Department of Health and Human Services. Mental health: culture, race, ethnicity—a supplement to mental health: a report of the surgeon general. 2001
Acknowledgements
This work was supported by the University of Iowa Holden Comprehensive Cancer Center Population Research Core (P30 CA086862), and the University of Iowa Medical Scientist Training Program (T32 GM007337). This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development, and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement # U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development, and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Dr. Fiedorowicz reports a consultation role with Myriad Genetics, Inc. (consultation for mood disorder proteomics study), as well as research funding from Myriad Genetics, Inc. (not applied to this work). Mr. Haskins, and Drs. McDowell, Carnahan, Wallace, Smith, and Chrischilles have no disclosures or conflict of interest to report.
Ethical standards
This study did not involve any direct human interventions. All research and analysis was performed in compliance with the current University of Iowa IRB regulations and laws of the United States.
Rights and permissions
About this article
Cite this article
Haskins, C.B., McDowell, B.D., Carnahan, R.M. et al. Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat 174, 197–208 (2019). https://doi.org/10.1007/s10549-018-5050-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-018-5050-1